Preoperative neutrophil/lymphocyte ratio as prognostic factor in epithelial ovarian cancer
DOI:
https://doi.org/10.18597/rcog.4046Abstract
Objectives: To determine if there is an association between the neutrophil to lymphocyte ratio (NLR) and prognosis in patients with epithelial ovarian cancer (EOC) diagnosed and treated in a Spanish population.
Material and methods: Retrospective cohort of patients with epithelial ovarian cancer who had neutrophil and lymphocyte values in complete blood count before the histopathological diagnosis and survival of at least three months, in an intermediate complexity hospital. Convenience sampling. Measured variables included age, menopausal stage, parity, International Federation of Gynecology and Obstetrics (FIGO) stage, treatment type, residual tumor, lymph node involvement, presence of ascites, cytology, histologic type, differentiation grade, and CA-125 values. Additionally, outcomes, overall survival, disease/progression-free survival were also measured. Bivariate inferential and Cox regression analyses were performed.
Results: Out of 78 candidates, 60 women with EOC were included. Of them, 24 (40%) had a low NLR (≤ 2,9) while 36 (60%) had a high NLR (> 2,9). An association was found between high NLR levels and suboptimal cytoreductive surgery. High NLR ratios were associated with lower overall survival (Hazard ratio (HR): 4.1; 95% CI: 1.4-11.8) and lower 5-year disease-free survival (HR: 2.6; 95% CI: 1.2-5.7).
Conclusions: A plasma neutrophil to lymphocyte ratio of more than 2.9 was associated with poor prognosis in patients with epithelial ovarian cancer in our setting. There is a need to establish the optimal cut-off point and conduct prospective studies with larger patient numbers in order to support this information.
References
Sung H, Ferlay J, Siegel L, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49. https://doi.org/10.3322/caac.21660.
Instituto Nacional de Estadística (INE), INEbase. Estadística de defunciones según la causa de muerte. Últimos datos [Internet]. 2023. INE. Disponible en: https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176780&menu=ultiDatos&idp=1254735573175
REDECAN. Estimaciones de la incidencia del cáncer en España [Internet]. 2020. Disponible en: https://redecan.org/redecan.org/es/estimaciones-incidencia2020.html?id=196&title=estimaciones-de-la-incidencia-del-c%C3%A1ncer-en-Espa%C3%B1a-2020.
Siegel L, Miller D, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30. https://doi.org/10.3322/caac.21590.
Buys S, Patridge E, Black A, Johnson C, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305:2295-303. https://doi.org/10.1001/jama.2011.766.
Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248-59. https://doi.org/10.1200/JCO.2002.20.5.1248.
Zhang W, Liu K, Hu G, Liang W. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. Tumour Biol. 2015;36:8831-7. https://doi.org/10.1007/s13277-015-3533-9.
Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539-45. https://doi.org/10.1016/S0140-6736(00)04046-0.
Grivennikov S, Greten F, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99. https://doi.org/10.1016/j.cell.2010.01.025.
Aggarwal B, Vijayalekshmi R, Sung B. Targeting Inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res. 2009;15:425-30. https://doi.org/10.1158/1078-0432.CCR-08-0149.
Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan D, Poggi A, et al. The ovarian cancer tumor immune microenvironment (TIME) as Target for therapy: A focus on innate immunity cells as therapeutic effectors. Int J Mol Sci. 2020;21. https://doi.org/10.3390/ijms21093125.
López J, Caicedo G, Velasco M, Ramírez L, Cárdenas L, Herrera J, et al. Relación neutrófilos-linfocitos en tumores sólidos. Rev Col Hematol Oncol. 2020;7:43-50. https://doi.org/10.51643/22562915.19.
Flores K, Monsalve N. Relación neutrófilos-linfocitos preoperatoria como factor pronóstico en pacientes con cáncer de endometrio. Rev Obstet Ginecol Ven. 2016;76:102-9.
Huang Q-T, Man Q-Q, Hu J, Yang Y, Zhang Y-M, Wang W, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies. Oncotarget. 2017;8:16755-64. https://doi.org/10.18632/oncotarget.15157.
Huang L, Mo Z, Zhang L, Qin S, Qin S, Li S. Diagnostic value of albumin to fibrinogen ratio in cervical cancer. Int J Biol Markers. 2020;35:66-73. https://doi.org/10.1177/1724600820915916.
Ni L, Tao J, Xu J, Yuan X, Long Y, Yu N, et al. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: A systematic review and meta-analysis. Arch Gynecol Obstet. 2020;301:251-61. https://doi.org/10.1007/s00404-019-05372-w.
Wang L, Liang D, Xu X, Jin J, Li S, Tian G, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. Oncol Lett. 2017;14:6449-56. https://doi.org/10.3892/ol.2017.7047.
Ocanto A, Debén B, Rodríguez I, Belinchón B, Glaría L, Morera R. Relación entre marcadores hematológicos y la respuesta patológica completa al tratamiento neoadyuvante en cáncer de recto localmente avanzado. JONNPR. 2020;5:1356-66. https://doi.org/10.19230/jonnpr.3754.
Williams K, Labidi-Galy S, Terry K, Vitonis A, Welch W, Goodman A, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132:542-50. https://doi.org/10.1016/j.ygyno.2014.01.026.
Templeton A, McNamara M, Šeruga B, Vera-Badillo F, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. https://doi.org/10.1093/jnci/dju124.
Guthrie G, Charles K, Roxburgh C, Horgan P, McMillan D, Clarke S. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218-30. https://doi.org/10.1016/j.critrevonc.2013.03.010.
Ethier J-L, Desautels D, Templeton A, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol. 2017;145:584-94. https://doi.org/10.1016/j.ygyno.2017.02.026.
Marchetti C, Romito A, Musella A, Santo G, Palaia I, Perniola G, et al. Combined plasma fibrinogen and neutrophil lymphocyte ratio in ovarian cancer prognosis may play a role? Int J Gynecol Cancer. 2018;28:939-44. https://doi.org/10.1097/IGC.0000000000001233.
Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, et al. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Sci Rep. 2020;10:18190. https://doi.org/10.1038/s41598-020-75316-x.
Gasparri M, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, et al. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev. 2015;16:3635-8. https://doi.org/10.7314/apjcp.2015.16.9.3635.
Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23:265. https://doi.org/10.3802/jgo.2012.23.4.265.
Thavaramara T, Phaloprakarn C, Tangjitgamol S, Manusirivithaya S. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai. 2011;94:871-7.
Zhang C, Jiang X, Li Y, Pan X, Gao M, Chen Y, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer: Recent clinical evidence and perspective focusing on NLR and PLR. J Ovar Res. 2023;16:36. https://doi.org/10.1186/s13048-023-01116-2.
Badora-Rybicka A, Nowara E, Starzyczny-Słota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. 2016;1:e000039. https://doi.org/10.1136/esmoopen-2016-000039.
Feng Z, Wen H, Bi R, Ju X, Chen X, Yang W, et al. Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer. PLoS One. 2016;11:e0156101. https://doi.org/10.1371/journal.pone.0156101.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Federación Colombiana de Obstetricia y Ginecología (FECOLSOG)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
